A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone

NCT02288247 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

688

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration Resistant Prostate Cancer

Interventions

DRUG: Enzalutamide
DRUG: Docetaxel
DRUG: Prednisolone
DRUG: Placebo

Sponsor

Astellas Pharma Europe Ltd.

Collaborators

[object Object]